164 related articles for article (PubMed ID: 33898999)
21. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
[TBL] [Abstract][Full Text] [Related]
23. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
24. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
25. [Experimental research on in vivo gene-therapy of retinoblastoma].
Chen D; Zhang X; Luo C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Aug; 16(4):211-5. PubMed ID: 10431044
[TBL] [Abstract][Full Text] [Related]
26. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
27. Disialoganglioside GD2 as a therapeutic target for human diseases.
Suzuki M; Cheung NK
Expert Opin Ther Targets; 2015 Mar; 19(3):349-62. PubMed ID: 25604432
[TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.
Omer B; Castillo PA; Tashiro H; Shum T; Huynh MTA; Cardenas M; Tanaka M; Lewis A; Sauer T; Parihar R; Lapteva N; Schmueck-Henneresse M; Mukherjee M; Gottschalk S; Rooney CM
Front Med (Lausanne); 2018; 5():343. PubMed ID: 30619856
[TBL] [Abstract][Full Text] [Related]
29. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
[TBL] [Abstract][Full Text] [Related]
30. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors.
Golinelli G; Grisendi G; Prapa M; Bestagno M; Spano C; Rossignoli F; Bambi F; Sardi I; Cellini M; Horwitz EM; Feletti A; Pavesi G; Dominici M
Cancer Gene Ther; 2020 Aug; 27(7-8):558-570. PubMed ID: 30464207
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
Louis CU; Savoldo B; Dotti G; Pule M; Yvon E; Myers GD; Rossig C; Russell HV; Diouf O; Liu E; Liu H; Wu MF; Gee AP; Mei Z; Rooney CM; Heslop HE; Brenner MK
Blood; 2011 Dec; 118(23):6050-6. PubMed ID: 21984804
[TBL] [Abstract][Full Text] [Related]
32. Retinoblastoma and tumor-suppressor gene therapy.
Xu HJ
Ophthalmol Clin North Am; 2003 Dec; 16(4):621-9. PubMed ID: 14741002
[TBL] [Abstract][Full Text] [Related]
33. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.
Gargett T; Yu W; Dotti G; Yvon ES; Christo SN; Hayball JD; Lewis ID; Brenner MK; Brown MP
Mol Ther; 2016 Jun; 24(6):1135-1149. PubMed ID: 27019998
[TBL] [Abstract][Full Text] [Related]
34. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
36. Ocular preservation in patients with bilateral retinoblastoma before chemotherapy in situ era: A report from a Mexican Retinoblastoma Reference Hospital.
Del Carmen Bernal-Díaz Z; Murillo-Maldonado MA; Pérez-Villanueva H; Reyes-López A; Ramírez-Ortiz MA
Pediatr Blood Cancer; 2020 Oct; 67(10):e28625. PubMed ID: 32743978
[TBL] [Abstract][Full Text] [Related]
37. Hydrogel implants for transscleral drug delivery for retinoblastoma treatment.
Cocarta AI; Hobzova R; Sirc J; Cerna T; Hrabeta J; Svojgr K; Pochop P; Kodetova M; Jedelska J; Bakowsky U; Uhlik J
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109799. PubMed ID: 31349439
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of B7H3 expression in retinoblastoma.
Ganesan B; Parameswaran S; Sharma A; Krishnakumar S
Sci Rep; 2020 Jun; 10(1):10185. PubMed ID: 32576886
[TBL] [Abstract][Full Text] [Related]
39. [Studies on thymidine kinase gene (TK) and GCV system for treatment of human retinoblastoma (RB)].
Liu J; Jing H; Zhang W; Liao S; Huang Q
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):300-3. PubMed ID: 12545814
[TBL] [Abstract][Full Text] [Related]
40. The development of young children with retinoblastoma.
Ross G; Lipper EG; Abramson D; Preiser L
Arch Pediatr Adolesc Med; 2001 Jan; 155(1):80-3. PubMed ID: 11177067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
